Biohaven is in late-stage human testing of a nasal spray version of its migraine drug zavegepant (formerly vazegepant) … more
Earlier this year the company reported that it had raised $60 million to bring the New Haven company’s drugs for migraine and other neurological diseases to the Asia-Pacific region … more